CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Virpax Pharmaceuticals, Inc. - VRPX CFD

    0.38
    9.52%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.42
    Open* 0.39
    1-Year Change* -50.63%
    Day's Range* 0.38 - 0.4
    52 wk Range 0.61-1.20
    Average Volume (10 days) 24.57K
    Average Volume (3 months) 537.74K
    Market Cap 7.27M
    P/E Ratio -100.00K
    Shares Outstanding 11.71M
    Revenue N/A
    EPS -1.30
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 0.38 -0.01 -2.56% 0.39 0.41 0.38
    Dec 4, 2023 0.42 0.04 10.53% 0.38 0.42 0.38
    Nov 29, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
    Nov 28, 2023 0.39 -0.09 -18.75% 0.48 0.48 0.39
    Nov 27, 2023 0.47 0.01 2.17% 0.46 0.47 0.46
    Nov 24, 2023 0.48 -0.03 -5.88% 0.51 0.52 0.48
    Nov 22, 2023 0.51 -0.05 -8.93% 0.56 0.56 0.45
    Nov 21, 2023 0.65 0.00 0.00% 0.65 0.65 0.65
    Nov 20, 2023 0.62 -0.06 -8.82% 0.68 0.68 0.61
    Nov 17, 2023 0.68 0.03 4.62% 0.65 0.68 0.65
    Nov 16, 2023 0.68 0.03 4.62% 0.65 0.77 0.65
    Nov 15, 2023 0.74 0.00 0.00% 0.74 0.74 0.74
    Nov 14, 2023 0.73 -0.03 -3.95% 0.76 0.76 0.73
    Nov 13, 2023 0.74 0.01 1.37% 0.73 0.74 0.73
    Nov 10, 2023 0.71 0.01 1.43% 0.70 0.71 0.70
    Nov 9, 2023 0.70 0.00 0.00% 0.70 0.70 0.70
    Nov 8, 2023 0.69 -0.03 -4.17% 0.72 0.74 0.69
    Nov 7, 2023 0.73 -0.02 -2.67% 0.75 0.76 0.73
    Nov 6, 2023 0.70 0.00 0.00% 0.70 0.70 0.70
    Nov 3, 2023 0.70 0.01 1.45% 0.69 0.70 0.69

    Virpax Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 21.8451 12.0255 4.19572 3.18187 2.62596
    Selling/General/Admin. Expenses, Total 11.0825 7.18639 2.9041 2.55913 1.48379
    Research & Development 10.7627 4.83912 1.29162 0.62274 1.14218
    Operating Income -21.8451 -12.0255 -4.19572 -3.18187 -2.62596
    Interest Income (Expense), Net Non-Operating 0 -0.09282 -0.14793 -0.12464 -0.01498
    Net Income Before Taxes -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Net Income After Taxes -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Net Income Before Extra. Items -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Net Income -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Income Available to Common Excl. Extra. Items -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Income Available to Common Incl. Extra. Items -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Diluted Net Income -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Diluted Weighted Average Shares 11.7122 6.67727 4.94515 4.94515 4.94515
    Diluted EPS Excluding Extraordinary Items -1.84856 -1.80554 -0.87756 -0.66864 -0.53405
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -1.84856 -1.80554 -0.87756 -0.66864 -0.53405
    Other, Net 0.19441 0.06226 0.004
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 3.23949 1.65107 3.10208 7.71514 5.90409
    Selling/General/Admin. Expenses, Total 1.9487 0.41545 1.74439 4.91004 2.64562
    Research & Development 1.29079 1.23561 1.35769 2.8051 3.25847
    Operating Income -3.23949 -1.65107 -3.10208 -7.71514 -5.90409
    Interest Income (Expense), Net Non-Operating 0 0 0
    Net Income Before Taxes -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Net Income After Taxes -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Net Income Before Extra. Items -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Net Income -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Income Available to Common Excl. Extra. Items -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Income Available to Common Incl. Extra. Items -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Diluted Net Income -3.11277 -1.52053 -2.98711 -7.64189 -5.88472
    Diluted Weighted Average Shares 11.7143 11.7143 11.7139 11.7134 11.7128
    Diluted EPS Excluding Extraordinary Items -0.26572 -0.1298 -0.25501 -0.65241 -0.50242
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.26572 -0.1298 -0.25501 -0.65241 -0.50242
    Other, Net 0.12672 0.13053 0.11497 0.07325 0.01937
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 19.6737 39.5724 0.07307 0.04672 0.0615
    Cash and Short Term Investments 18.9953 36.842 0.0548 0.04154 0.04837
    Cash 18.9953 36.842 0.0548 0.04154 0.04837
    Total Receivables, Net 0 0.00139 0
    Accounts Receivable - Trade, Net 0 0.00139 0
    Prepaid Expenses 0.65302 2.61894 0.00879 0.0038 0.00263
    Other Current Assets, Total 0.02534 0.1115 0.00948 0 0.0105
    Total Assets 19.6737 39.5724 0.46541 0.04672 0.0615
    Total Current Liabilities 3.09459 2.08769 3.65991 2.77899 1.25422
    Accrued Expenses 0.65477 0.62728 0.27 0.81916 0.30572
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.54399 1.26452 0.5
    Other Current Liabilities, Total 2.43983 1.46041 2.84592 0.69531 0.44851
    Total Liabilities 3.09459 2.08769 4.6815 2.77899 1.25422
    Total Long Term Debt 0 0 1.02159 0 0
    Total Equity 16.5791 37.4847 -4.2161 -2.73228 -1.19272
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.00012 0.00012 0.00003 0.00015 0.00014
    Additional Paid-In Capital 60.9336 60.1885 6.43172 3.57577 1.80881
    Retained Earnings (Accumulated Deficit) -44.3546 -22.7039 -10.6478 -6.30819 -3.00168
    Total Liabilities & Shareholders’ Equity 19.6737 39.5724 0.46541 0.04672 0.0615
    Total Common Shares Outstanding 11.7143 11.7149 4.94515 4.94515 4.94515
    Other Long Term Assets, Total 0 0.39234
    Long Term Debt 0 1.02159
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total Current Assets 15.9514 18.4933 19.6737 23.6358 29.4024
    Cash and Short Term Investments 14.804 16.9869 18.9953 20.5626 26.0611
    Cash 14.804 16.9869 18.9953 20.5626 26.0611
    Prepaid Expenses 1.10229 1.47637 0.65302 3.04688 3.33408
    Other Current Assets, Total 0.04508 0.03006 0.02534 0.02627 0.00723
    Total Assets 15.9514 18.4933 19.6737 23.6358 29.4024
    Other Long Term Assets, Total
    Total Current Liabilities 3.64677 3.29424 3.09459 4.20787 2.48337
    Accrued Expenses 0.63634 0.16409 0.65477 0.31123 0.23561
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 3.01043 3.13015 2.43983 1.89664 2.24776
    Total Liabilities 3.64677 3.29424 3.09459 4.20787 2.48337
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Total Equity 12.3046 15.1991 16.5791 19.4279 26.9191
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 0.00012 0.00012 0.00012 0.00012 0.00012
    Additional Paid-In Capital 61.2924 61.0742 60.9336 60.7953 60.6446
    Retained Earnings (Accumulated Deficit) -48.9879 -45.8752 -44.3546 -41.3675 -33.7256
    Total Liabilities & Shareholders’ Equity 15.9514 18.4933 19.6737 23.6358 29.4024
    Total Common Shares Outstanding 11.7143 11.7143 11.7143 11.7144 11.7146
    Payable/Accrued 2
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -21.6507 -12.0561 -4.33965 -3.30651 -2.64094
    Cash From Operating Activities -17.8467 -14.5426 -1.38486 -1.13183 -1.79964
    Non-Cash Items 0.74503 0.91242 1.62686 1.24279 0.39993
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0.36282 0 0 0
    Changes in Working Capital 3.05898 -3.39895 1.32793 0.93189 0.44137
    Cash From Financing Activities 0 51.3298 1.39812 1.125 1.67477
    Issuance (Retirement) of Stock, Net 0 58.02 1.3769 0.625 1.12
    Issuance (Retirement) of Debt, Net 0 -1.50376 0.0721 0.5 0.55477
    Net Change in Cash -17.8467 36.7872 0.01326 -0.00683 -0.12487
    Financing Cash Flow Items 0 -5.18645 -0.05088
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -1.52053 -21.6507 -18.6636 -11.0217 -5.137
    Cash From Operating Activities -2.00837 -17.8467 -16.2794 -10.7809 -6.04486
    Non-Cash Items 0.14058 0.74503 0.60676 0.45604 0.21134
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0 0 0 0
    Changes in Working Capital -0.62842 3.05898 1.77747 -0.21518 -1.1192
    Cash From Financing Activities 0 0 0 0
    Financing Cash Flow Items 0 0 0 0
    Issuance (Retirement) of Stock, Net 0 0 0 0
    Issuance (Retirement) of Debt, Net 0 0 0 0
    Net Change in Cash -2.00837 -17.8467 -16.2794 -10.7809 -6.04486
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Virpax Pharmaceuticals LLC Corporation 23.3086 2730438 0 2023-05-30 LOW
    Sabby Management, LLC Investment Advisor/Hedge Fund 3.4146 400000 -588165 2023-06-30 HIGH
    Mack (Anthony P.) Individual Investor 2.156 252562 0 2023-05-30 LOW
    PNC Investments LLC Investment Advisor 0.8611 100875 0 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 0.7628 89354 -5946 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.5637 66038 0 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.5561 65145 0 2023-06-30 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1299 15221 0 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.102 11953 11953 2023-06-30 HIGH
    Quantum Private Wealth, LLC Investment Advisor 0.0854 10000 0 2023-06-30 LOW
    Sendrow (Jerrold B) Individual Investor 0.0769 9006 0 2023-05-30 LOW
    Floyd (Eric) Individual Investor 0.0685 8023 0 2023-05-30 LOW
    Gudin (Jeffrey) Individual Investor 0.0647 7584 0 2023-05-30 LOW
    Tower Research Capital LLC Hedge Fund 0.0464 5433 -30 2023-06-30 HIGH
    Bruce (Gerald W) Individual Investor 0.0345 4045 0 2023-05-30 LOW
    Osaic Holdings, Inc. Investment Advisor 0.0051 600 0 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.004 464 0 2023-06-30 LOW
    Morgan Stanley Smith Barney LLC Investment Advisor 0.0013 150 0 2023-06-30 LOW
    Jambulingam (Thani) Individual Investor 0.0009 100 0 2023-05-30 LOW
    Wells Fargo Bank, N.A. Bank and Trust 0.0005 62 2 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Virpax Pharmaceuticals, Inc. Company profile

    Founded in 2016, Virpax Pharmaceuticals (VRPX) is a preclinical stage biopharmaceutical company that develops and manufactures novel and proprietary drug delivery systems for non-opioid and non-addictive pain treatments.

    Based in Berwyn, Pennsylvania, US, Virpax has global rights to the following patented pain management technologies:

    • Epoladerm – A topical nonsteroidal anti-inflammatory drug candidate for treatment of chronic osteoarthritis of the knee. It is used once a day.

    • Probudur – Injectable local anaesthetic Lipoal Gel Technology for postoperative pain management. The company plans to market this drug candidate to general surgeons, anesthesiologists and orthopaedic surgeons with the local anaesthetic postsurgical market, valued at $577m (£451m) as of 2019. The company believes Probudur can eliminate the need for opioids for postoperative pain relief.

    • Envelta – A Molecular Envelope Technology (MET) that delivers enkephalin for the management of acute and chronic pain, including cancer-induced pain, using an intranasal device. Virpax has identified a significant unmet need and market opportunity for current opioid prescribers, such as pain and hospice treatment centres.

    • AnQlar – A nasal spray that is being developed as an anti-viral barrier to potentially prevent or reduce the severity of viral infections in humans. The company has completed toxicology and ex-vivo studies on AnQlar, which show a reduction in infectivity from respiratory viruses such as influenza and SARS-CoV-2.

    • VRP324 – An investigational formulation designed to improve cannabidiol (CBD) transport to the brain via the nasal route. VRP324 propels the CBD powder formulation into the nose and into the brain via the olfactory nerve/bulb using a preassembled device and cartridge. This product candidate can potentially treat seizures associated with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in patients aged one year and older. CBD is a substance found in cannabis.

    Virpax went public on 16 February 2021. Its stock is listed on the Nasdaq capital market under the ticker symbol ‘VRPX’.

    Industry: Biotechnology & Medical Research (NEC)

    1055 Westlakes Drive, Suite 300
    BERWYN
    PENNSYLVANIA 19312
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Gold

    2,004.85 Price
    -1.180% 1D Chg, %
    Long position overnight fee -0.0198%
    Short position overnight fee 0.0116%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    44,039.40 Price
    -1.250% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading